Search

Displaying results 2251 - 2260 of 10000 in total
  1. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. … [L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS).

  2. Drug

    Tapinarof

    go.drugbank.com/drugs/DB06083
    ApprovedInvestigational

    [A248790] Tapinarof received initial approval from the FDA in 2022.[L41845] … Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis.

  3. Drug

    Picrotoxin

    go.drugbank.com/drugs/DB00466
    Experimental

    Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    patients taking gatifloxacin compared to those on macrolide antibiotics. … It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    in the central nervous system and in the body. … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity

  6. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.

  7. Drug

    Vaborbactam

    go.drugbank.com/drugs/DB12107
    ApprovedInvestigational

    [A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. … Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.

  8. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated

  9. Drug

    Isoflurophate

    go.drugbank.com/drugs/DB00677
    ApprovedWithdrawn

    Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330) … An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma.

  10. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.

    Products: Copaxone 20 mg/ml Injektionslösung in einer Fertigspritze, Copaxone 40 mg/ml Injektionslösung in einer Fertigspritze